ELCO Management’s Lineage Cell Therapeutics LCTX Stock Holding History

ELCO Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14.3K	Hold	15,000	–	–	0.01%	171
2026 Q2	$19.6K	Sell	15,000 -5,500	-27%	-$7.6K	0.01%	173
2026 Q1	$32.4K	Hold	20,500	–	–	0.02%	169
2025 Q4	$34.2K	Buy	20,500 +500	+3%	+$865	0.02%	156
2025 Q3	$33.8K	Buy	20,000 +3,800	+23%	+$4.5K	0.02%	162
2025 Q2	$14.7K	Buy	16,200 +1,300	+9%	+$771	0.01%	156
2025 Q1	$6.73K	Hold	14,900	–	–	﹤0.01%	155
2024 Q4	$7.49K	Buy	14,900 +2,900	+24%	+$2.13K	﹤0.01%	158
2024 Q3	$10.9K	Hold	12,000	–	–	0.01%	163
2024 Q2	$12K	Hold	12,000	–	–	0.01%	156
2024 Q1	$17.8K	Hold	12,000	–	–	0.01%	154
2023 Q4	$13.1K	Hold	12,000	–	–	0.01%	142
2023 Q3	$14.2K	Hold	12,000	–	–	0.01%	135
2023 Q2	$16.9K	Hold	12,000	–	–	0.01%	128
2023 Q1	$18K	Hold	12,000	–	–	0.01%	136
2022 Q4	$16.7K	Hold	12,000	–	–	0.01%	137
2022 Q3	$14K	Buy	+12,000	New	+$17.6K	0.01%	139

Other funds holding LCTX

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return

Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ELCO Management's LCTX Position: Q3 2026 in Review

ELCO Management held its Lineage Cell Therapeutics (LCTX) position steady in Q3 2026 at 15,000 shares worth $14.3K. The position accounts for 0.01% of the portfolio, ranked #171.

ELCO Management first reported a position in LCTX in Q3 2022 and has held it in 17 quarters since. The position peaked at $34.2K in Q4 2025. 87 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

ELCO Management held 15,000 shares of Lineage Cell Therapeutics worth $14.3K as of Q3 2026.
ELCO Management left its Lineage Cell Therapeutics share count unchanged in Q3 2026.
Lineage Cell Therapeutics made up 0.01% of ELCO Management's portfolio in Q3 2026, its #171 holding.
ELCO Management first reported a position in Lineage Cell Therapeutics in Q3 2022 and has held it in 17 quarters since.
ELCO Management's Lineage Cell Therapeutics position peaked at $34.2K in Q4 2025.
87 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on ELCO Management's 13F filing for Q3 2026, filed 14 Oct 2026.